These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 30056030)

  • 1. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
    Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
    Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
    J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
    Ferrante M; Irving PM; Abreu MT; Axler J; Gao X; Cao Q; Fujii T; Rausch A; Torres J; Neimark E; Song A; Wallace K; Kligys K; Berg S; Liao X; Zhou Q; Kalabic J; Feagan B; Panaccione R
    J Crohns Colitis; 2024 Mar; 18(3):416-423. PubMed ID: 37797293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose naltrexone for induction of remission in Crohn's disease.
    Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.